Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Current treatment options for metastatic head and neck cancer.

Price KA, Cohen EE.

Curr Treat Options Oncol. 2012 Mar;13(1):35-46. doi: 10.1007/s11864-011-0176-y. Review.

PMID:
22252884
2.

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sacco AG, Cohen EE.

J Clin Oncol. 2015 Oct 10;33(29):3305-13. doi: 10.1200/JCO.2015.62.0963. Epub 2015 Sep 8. Review.

PMID:
26351341
3.

Recurrent head and neck cancer: current treatment and future prospects.

Specenier PM, Vermorken JB.

Expert Rev Anticancer Ther. 2008 Mar;8(3):375-91. doi: 10.1586/14737140.8.3.375. Review.

PMID:
18366286
4.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

5.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.

6.

Current chemotherapies for recurrent/metastatic head and neck cancer.

Molin Y, Fayette J.

Anticancer Drugs. 2011 Aug;22(7):621-5. doi: 10.1097/CAD.0b013e3283421f7c. Review.

PMID:
21131821
7.

Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.

Oncol Rep. 2011 Nov;26(5):1099-109. doi: 10.3892/or.2011.1403. Epub 2011 Jul 26.

PMID:
21805039
8.
9.

Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Aderhold C, Umbreit C, Faber A, Sauter A, Sommer JU, Birk R, Erben P, Hofheinz RD, Stern-Straeter J, Hörmann K, Schultz JD.

Anticancer Res. 2013 May;33(5):1951-61.

PMID:
23645743
10.

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS.

J Clin Oncol. 2005 Aug 20;23(24):5578-87. Epub 2005 Jul 11.

PMID:
16009949
11.

Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A.

J Clin Oncol. 2005 Aug 20;23(24):5568-77. Epub 2005 Jul 11.

PMID:
16009950
12.

Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.

Bernier J.

Nat Clin Pract Oncol. 2008 Dec;5(12):705-13. doi: 10.1038/ncponc1228. Epub 2008 Sep 30. Review.

PMID:
18825142
13.
14.

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.

Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.

Cancer. 1999 Dec 1;86(11):2364-9.

PMID:
10590379
15.

Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.

Caponigro F, Milano A, Basile M, Ionna F, Iaffaioli RV.

Curr Opin Oncol. 2006 May;18(3):247-52. Review.

PMID:
16552236
16.

Current concepts for the management of head and neck cancer: chemotherapy.

Specenier PM, Vermorken JB.

Oral Oncol. 2009 Apr-May;45(4-5):409-15. doi: 10.1016/j.oraloncology.2008.05.014. Epub 2008 Aug 19. Review.

PMID:
18715812
17.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
18.

Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.

de Andrade DA, Machiels JP.

Curr Opin Oncol. 2012 May;24(3):211-7. doi: 10.1097/CCO.0b013e3283510773. Review.

PMID:
22498572
20.

Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.

Rangaraju RR, Sharma JB, Dewan AK, Anand AK, Sheh R, Jena A, Chaturvedi AK.

Indian J Cancer. 2012 Jan-Mar;49(1):1-5. doi: 10.4103/0019-509X.98906.

Supplemental Content

Support Center